2022 in review: Regulation starts to catch up with AI in pharma
Pharmaceutical Technology
DECEMBER 21, 2022
According to a cross-sectorial survey by the consulting firm Mckinsey & Company , 52% of respondents reported investing in AI this year compared to 40% in 2018. This could spell high-stake consequences for consumers whose privacy and safety could be at risk if AI models are not regulated. FDA and EMA action.
Let's personalize your content